FDA

#AI #Cancer #CNS #FDA #Lantern Pharma #Solid tumours

FDA clearance of IND application for solid tumour drug 

Lantern Pharma, an AI company developing targeted and transformative cancer therapies, has received clearance from the US Food and Drug Administration (FDA) for the investigational new drug (IND) application for LP-184, which is being developed for multiple advanced solid tumours and central nervous system (CNS) cancers.   The… Read More

#News

#AstraZeneca #Drug development #FDA #GSK #HER2 #National Institute for Health and Care Excellence (NICE) #Pfizer #Regulatory

This week in drug discovery (12-16 June)  

News round-up for 5-9 June by DDW Multimedia Editor Megan Thomas.  Regulatory approvals and industry guidelines are key to the continued development and discovery of drugs, which is a common theme throughout this week’s news highlights, including an FDA approval for Pfizer, a NICE recommendation… Read More

#News

Respiratory syncytial virus
#FDA #GSK #Immunology / Virology & Vaccines #Pfizer #Respiratory syncytial virus

GSK faces RSV vaccine threat from rival Pfizer  

An FDA approval for Pfizer’s Abrysvo respiratory syncytial virus (RSV) vaccine is likely to threaten GSK’s current hold on the market, according to GlobalData.  GSK received approval by the European Commision (EC) for its vaccine Arexvy, which targets the prevention of lower respiratory tract infections (LRTI) caused by RSV in… Read More

#News #Regulatory #Trending News

#Cancer research #Clinical trial design #Clinical trials #FDA #Phase I trial

New DDW Highlights podcast for 12 June 2023

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  There has been some interesting news related to clinical trials this week, with the announcement that… Read More

#News

#FDA #Minoryx Therapeutics #Neurodegenerative disorders #Phase III trial #Rare disease

FDA approves Phase III cerebral Adrenoleukodystrophy trial

The US Food and Drug Administration (FDA) has approved Minoryx Therapeutics’ Phase III clinical trial (CALYX) of leriglitazone, to treat adult male X-linked Adrenoleukodystrophy (X-ALD) patients with cerebral Adrenoleukodystrophy (cALD). Patient recruitment is expected to start by the end of Q2 2023 with results anticipated by late 2025. Marc Martinell,… Read More

#News #Regulatory

#Cancer research #Clinical trial design #Clinical trials #FDA #Phase I trial

This week in drug discovery (5-9 June)

News round-up for 5-9 June by DDW Digital Content Editor Diana Spencer. There has been some interesting news related to clinical trials this week, with the announcement that the FDA has published draft guidance to modernise the design and conduct of studies, and the failure of… Read More

#News

siRNA
#DTx Pharma #FDA #Orphan drugs #Rare disease #siRNA

siRNA therapy for rare disease granted orphan status

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to DTx Pharma’s DTx-1252, an investigational small interfering RNA (siRNA) therapeutic for the treatment of Charcot-Marie-Tooth Disease Type 1A (CMT1A). CMT1A is a progressive, neuromuscular, autosomal-dominant disease that leads to life-long loss of muscle… Read More

#News

FDA
#AI / data analytics / healthtech / informatics #Clinical trial design #Clinical trials #Digitalisation #FDA

FDA announces additional steps to modernise clinical trials

The US Food and Drug Administration has published draft guidance with updated recommendations for good clinical practices (GCPs) to modernise the design and conduct of clinical trials. The updates are intended to help pave the way for more efficient clinical trials. The draft guidance is adopted from the International Council… Read More

#Editor's Choice #News #Regulatory

Vaccine
#FDA #Immunology / Virology & Vaccines #Pfizer #Phase III trial #Respiratory syncytial virus

FDA approves first vaccine for respiratory syncytial virus

The US Food and Drug Administration (FDA) has approved Pfizer’s bivalent respiratory syncytial virus (RSV) prefusion F (RSVpreF) vaccine Abrysvo in individuals 60 years and older. Abrysvo is unadjuvanted and composed of two preF proteins selected to optimise protection against RSV A and B strains and… Read More

#News #Trending News

Male patient with doctor
#AstraZeneca #FDA #Merck #Oncology #Phase III trial #Prostate cancer

FDA extends US approval for olaparib in prostate cancer

Lynparza (olaparib) has been approved in the US for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). The PARP inhibitor, developed by AstraZeneca and Merck (MSD), is approved in combination with abiraterone and prednisone or prednisolone. This approval was based on… Read More

#News #Regulatory

US Food and Drug Administration
#FDA #Gene therapy #Krystal Biotech #Rare disease

FDA approves first gene therapy for rare skin disorder

The US Food and Drug Administration has approved Krystal Biotech’s Vyjuvek, a herpes-simplex virus type 1 (HSV-1) vector-based gene therapy, for the treatment of dystrophic epidermolysis bullosa (DEB). It is approved for treating wounds in patients six months of age and older with mutation(s) in the collagen type VII alpha… Read More

#News #Regulatory #Trending News

DNA vector
#Cell and gene therapy #FDA #Gene therapy #Muscular dystrophy #Sarepta Therapeutics

FDA committee supports gene therapy for muscular dystrophy

The US Food and Drug Administration (FDA) Cellular, Tissue and Gene Therapies Advisory Committee (CTGTAC) have voted eight to six in favour of a new gene therapy for Duchenne muscular dystrophy. The vote supports the accelerated approval of Sarepta Therapeutics’ SRP-9001 (delandistrogene moxeparvovec) for the treatment of ambulatory patients with… Read More

#News #Regulatory #Trending News

siRNA
#FDA #Orphan drugs #Paediatrics #Rare disease #siRNA #SiSaf

Therapy for rare skeletal disorder granted orphan status

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to SiSaf’s small interfering RNA (siRNA) therapeutic for skeletal disorder Autosomal Dominant Osteopetrosis Type 2 (ADO2). In addition, due to the serious manifestations of this rare disease in children, SIS-101-ADO has been granted Rare Pediatric Disease Designation for… Read More

#News #Regulatory

Dementia
#Alzheimer's #Dementia #FDA #Lundbeck #Otsuka #Phase III trial

FDA approves first drug for agitation due Alzheimer’s dementia

Otsuka and Lundbeck’s Rexulti (brexpiprazole) has become the first pharmacological treatment to be approved in the US for agitation associated with dementia due to Alzheimer’s disease. The Food and Drug Administration (FDA) has approved the companies’ supplemental New Drug Application (sNDA). Agitation is a common neuropsychiatric symptom in Alzheimer’s dementia… Read More

#News #Regulatory

Animal testing
#Animal models #Animal testing #Cellular assays #FDA #Organoids #Preclinical investigations

FDA Modernization Act 2.0: A step in the right direction

By DDW Editor Reece Armstrong A lot has already been said about the US Food and Drug Administration’s (FDA) Modernization Act 2.0 and for good reason. The decision by the Biden administration to end the federal requirement for drugs under development to be tested on animals represents a significant step forward for the… Read More

#Exclusive Content